Ezogelin Oflazoglu-Gruyters, Ph.D., is head of external development and product development team lead at MedImmune, the global Biologics research and development arm of AstraZeneca. She is responsible for providing cross-functional leadership through approval of IO programs in the Oncology portfolio and external development. She has been a member and contributor on the Medimmune Oncology leadership team developing strategy and implementing oncology program development for IO and ADCs. Dr. Oflazoglu-Gruyters received her B.S. degree in Biological Sciences from Middle East Technical University, Ankara, Turkey and her Ph.D. in the field of Immunology from Roswell Park Cancer Institute, State University of New York at Buffalo. Prior to joining MedImmune in 2017, she worked in biotech and pharmaceutical industries such as Immunex/Amgen and Seattle Genetics, Merck and Celgene initially focusing her efforts on the discovery and validation of novel therapeutic targets in inflammation and oncology. She then moved on to develop novel and biosimilar therapeutics in a variety of solid tumors and hematologic malignancies including Adcetris, Keytruda, Vidaza. Ezo has over 20 years of research and industry experience in the field of Biologics, IO and ADCs.